AnneKerneur

Counsel

Paris + 33.1.56.59.39.39

Connect:

Share

Anne Kerneur's practice focuses on venture capital, capital markets, and M&A. For more than a decade she has represented technology, life sciences, and other growth enterprises, as well as the venture firms and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to listed companies.

Anne's experience includes advising high-growth companies in connection with their financing rounds such as Ankorstore, Shippeo, Akeneo, and TreeFrog Therapeutics and venture capital investors such as Alven, Creadev, ETF, Hi Inov, Idinvest / Eurazeo, Quadrant Management, Ring Capital, Sofinnova Partners, and Seventure.

Illustrative transactions in which Anne acted as co-lead lawyer includes: the EUR 250 million financing round of Ankorstore lead by Bond and Tiger, the EUR 35 million financing round of Selency lead by Creadev, the EUR 15 million financing round of GFBiochemicals lead by Sofinnova and Sparta, the USD 45 million financing round of Wandercraft by Quadrant Management, and the acquisition of Potager City by Carrefour. Anne also advised Integragen in connection with the successful public tender offer of shares by OncoDNA and Deutsche Bank and Société Générale in connection with the €165 million initial public offering by DEE Tech, the first ever French SPAC (special purpose acquisition company) in the tech sector. She also worked on the IPO of Criteo on Nasdaq and the recent IPO of EUROAPI on the main French market.

Experience

  • Ring invests €6 million in LeHibouJones Day advised Ring Capital in the €6 million financing of LeHibou, an intermediation platform between IT freelancers and large companies.
  • Seventure leads €7 million Series A financing round of JolimoiJones Day advised Seventure Partners as lead investor in the €7 million Series A financing round of Jolimoi, a French start-up company engaged in the business of direct and e-commerce sale of multi-brand beauty and lifestyle products using social selling and the development of self-service (SaaS) technological solutions for clients using social selling in the beauty domain.
  • Hi Inov, Omnes, and Swen Capital Partners invest in SkillupJones Day represented Hi Inov, Omnes, and Swen Capital Partners in connection with the €8 million round of financing along with existing investors Global Founders Capital and Kerala in Skillup, a human resource talent management SaaS.
  • Creadev leads €35 million investment in SelencyJones Day represented Creadev as lead investor with Accel in the €35 million Series B round of financing of Selency, a Paris-based impact e-commerce platform and Europe's leading marketplace for second-hand furniture and home decor.
  • Sofinnova leads €15 million Series A financing round of GFBiochemicalsJones Day advised Sofinnova Partners, as lead investor, with participation from Sparta Capital, in the €15 million Series A financing round of GFBiochemicals to accelerate GFBiochemicals' mission to end chemical pollution by helping fast moving consumer goods (FMCG) and industrial companies transition away from using toxic, environmentally harmful petrochemicals in everyday products.
  • Hi Inov participates in €150 million Series C financing round of DeepkiJones Day advised Hi Inov in connection with its participation in the €150 million Series C financing round of Deepki, a French start-up company operating an ESG data intelligence platform for the real estate sector, led by One Peak and Highland Europe.
  • Quadrant Management participates in $45 million Series C financing round of WandercraftJones Day advised Quadrant Management in connection with its participation in a $45 million Series C financing round of Wandercraft, a leading healthtech company in dynamic robotic and exoskeleton technology.
  • Ankorstore raises €250 million in Series C financing roundJones Day advised Ankorstore, a French company developing and operating marketplaces whose purpose is to connect brands and designers with professionals, notably through digital platforms, in connection with its €250 million Series C round of financing led by BOND and Tiger Global.
  • Mérieux Equity Partners leads $150 million growth financing of DentalMonitoringJones Day advised Mérieux Equity Partners in leading the $150 million growth financing of DentalMonitoring, a leading AI-based dental software company monitoring the dental and orthodontics fields, thus granting DentalMonitoring a well-deserved unicorn status, as the second French HealthTech company reaching this type of valuation.
  • TreeFrog Therapeutics raises €64 million in Series B financing roundJones Day represented TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, in connection with its €64 million Series B financing round led by Bpifrance Large Venture and joined by Leonard Green & Partners L.P., Bristol Myers Squibb, and XAnge.
  • Deutsche Bank and Société Générale underwrite €165 million SPAC IPO by DEE TechJones Day represented Deutsche Bank, as sole global coordinator and joint bookrunner, and Société Générale, as joint bookrunner, in connection with the €165 million initial public offering by DEE Tech, the first ever French SPAC in the tech sector, which will be listed on the Professional Segment of the regulated market of Euronext Paris.
  • Ankorstore raises $100 million in Series B financing roundJones Day advised Ankorstore, a French company developing and operating marketplaces whose purpose is to connect brands and designers with professionals, notably through digital platforms, in connection with its $100 million Series B round of financing led by Tiger Global and Bain Capital Ventures.
  • IntegraGen’s shareholders sell majority interest to OncoDNA in tender offerJones Day advised IntegraGen, a biotechnology company developing molecular markers for central nervous system and metabolic diseases, in connection with the public tender offer of shares by OncoDNA, a private health technology and precision medicine company focused on oncology.
  • Hi Inov leads $3.8 million Series A financing round of Per AngustaJones Day advised Hi Inov as lead investor in connection with the $3.8 million Series A financing round of Per Angusta, a French company that designs and markets SaaS software for the performance of purchasing teams.
  • Sofinnova participates in $5.6 million Series A financing round of Protera BioJones Day advised Sofinnova Partners in connection with the $5.6 million Series A financing round of Protera Bio, an Al-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions.
  • Ring Capital, SEB Alliance, Amundi Finance et Solidarité, and Raise Impact participate in €13.5 million financing round of CastalieJones Day represented Ring Capital, SEB Alliance, Amundi Finance et Solidarité, and Raise Impact in connection with the €13.5 million round of financing of Castalie, a French company engaged in the development, manufacturing, and marketing of water fountains and water cooling.
  • SymBiosis participates in €18 million Series B financing round of MaaT PharmaJones Day advised SymBiosis LLC, as lead investor, in connection with the €18 million Series B round of financing of MaaT Pharma, a French clinical-stage company developing microbiome-based biotherapeutics.
  • Carrefour acquires Potager CityJones Day advised Carrefour Group in its acquisition of Potager City, a French distributor of online subscription-based boxes of extra-fresh and seasonal fruit and vegetables sourced via short distribution channels.
  • Alven Capital invests in CardiologsJones Day represented Alven Capital SA in connection with its investment in Cardiologs, a company engaged in the development of an AI-based heart disease diagnostic solution by supporting physicians with unprecedented EKG data analysis and reporting capabilities.
  • Novo Holdings REPAIR Impact Fund invests €7 million in MutabilisJones Day advised Novo Holdings REPAIR Impact Fund in connection with the €7 million convertible financing of Mutabilis, a French company engaged in the development of novel antibacterials against Gram-negative infections.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.